Novartis and NHIA forge groundbreaking partnership to combat cardiovascular disease in Taiwan

5 November 2025

In a bold step toward transforming cardiovascular care, Novartis Taiwan has joined forces with the National Health Insurance Administration (NHIA) to tackle atherosclerotic cardiovascular disease (ASCVD)—Taiwan’s leading health threat. This first-of-its-kind public-private partnership is more than a milestone; it’s a commitment to improving heart health outcomes in Taiwan.

Together, Novartis and NHIA are reshaping how heart health is managed—through data integration, a nationally endorsed clinical pathway, and a new LDL-C goal attainment incentive program for healthcare professionals. Announced on World Heart Day 2024, this initiative empowers physicians to “treat to target” and encourages patients to take charge of their heart health.

Beyond this, the collaboration also initiated a transformative shift towards a proactive model of care, demonstrating how bold partnerships can help unblock better outcomes – for patients, providers and public health.